Ads
related to: metastatic nsclc survival rates chart for cancer diagnosis- 2L mNSCLC Treatment
For Metastatic
NSCLC. Visit Physician Site.
- mNSCLC Biomarker Info
Discover A Treatment For 2L mNSCLC
With This Actionable Biomarker
- Mechanism Of Action Info
See How A 2L Metastatic
NSCLC Therapy Works.
- Dosing & Administration
View Dosing & Preparation Info For
A 2L mNSCLC Treatment Option.
- Resources For Physicians
Downloadable Resources For Your
mNSCLC Patients & Their Caregivers.
- Efficacy & Safety Data
See If A 2L mNSCLC Treatment
Is An Option For Your Patients.
- 2L mNSCLC Treatment
Search results
Results From The WOW.Com Content Network
Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. [1] [2] [3] As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma.
In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [1] Below is an incomplete list of age-adjusted mortality rates for different types of cancer in the United States from the Surveillance, Epidemiology, and End Results program.
The initial evaluation of non-small cell lung cancer staging uses the TNM classification. This is based on the size of the primary tumor, lymph node involvement, and distant metastasis. After this, using the TNM descriptors, a group is assigned, ranging from occult cancer, through stage 0, IA (one-A), IB, IIA, IIB, IIIA, IIIB to IV (four).
There are two main types of lung cancer, categorized by the size and appearance of the malignant cells seen by a histopathologist under a microscope: small cell lung cancer (SCLC; 15% of cases) and non-small-cell lung cancer (NSCLC; 85% of cases). [18] SCLC tumors are often found near the center of the lungs, in the major airways. [19]
In the United States there has been an increase in the 5-year relative survival rate between people diagnosed with cancer in 1975-1977 (48.9%) and people diagnosed with cancer in 2007-2013 (69.2%); these figures coincide with a 20% decrease in cancer mortality from 1950 to 2014. [8]
It's 50% to 80% of patients with oncology, suffer from that, particularly, as you know, within pancreatic and non-small cell lung cancer. It's probably about 20% to 30% in heart failure and COPD.
Ads
related to: metastatic nsclc survival rates chart for cancer diagnosis